<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532518</url>
  </required_header>
  <id_info>
    <org_study_id>NIC-04</org_study_id>
    <nct_id>NCT01532518</nct_id>
  </id_info>
  <brief_title>Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance</brief_title>
  <official_title>A Multicenter, Open Label, Ascending 7 Day-Repeated Dose Study to Investigate Efficacy, Safety and Pharmacokinetics of Nepadutant In Infants With Feeding Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present pilot study is aimed to obtain preliminary data on the effect of three ascending&#xD;
      oral dose levels of nepadutant on the relief of symptoms associated with feeding intolerance.&#xD;
      In addition, the assessment of drug exposure (PK assessment) will provide additional&#xD;
      information on the dose-effect relationship, thus supporting the dose selection and dosing&#xD;
      schedule in the future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Feeding intolerance is a transient neuro-developmental phenomenon affecting 25% to 40% of&#xD;
      infant and toddler, with a peak at 6 weeks of age. Feeding problems include mainly vomiting,&#xD;
      slow feeding, refusal to eat and colic.&#xD;
&#xD;
      Current non pharmacological interventions (e.g. message, restriction in maternal diet in&#xD;
      breast-feeding infants) and pharmacological treatments (simethicone, antimuscarinic drugs and&#xD;
      antiacids) are largely unsatisfactory.&#xD;
&#xD;
      Nepadutant is postulated to have a therapeutic effect in infant colic since it reverts&#xD;
      exaggerated intestinal motility and sensitivity induced by different stimuli through the&#xD;
      activation of neurokinin-2 receptors, without interferring on the on physiological&#xD;
      gastrointestinal transit.&#xD;
&#xD;
      This phase IIa study is designed to test in each participant infant two out of three oral&#xD;
      doses of nepadutant in order to measure its blood levels, safety and efficacy with each dose&#xD;
      level to be given for 7 concecutive days.&#xD;
&#xD;
      The experimental clinical phase encompasses the following periods:&#xD;
&#xD;
        -  Screening period (no study medication), lasting approximately 7 days prior to&#xD;
           randomization&#xD;
&#xD;
        -  Treatment period, lasting fourteen days (7 days fore each dose)with once daily&#xD;
           administration&#xD;
&#xD;
        -  A safety follow-up visit, approximately four weeks after start of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Infant Gastroesophageal reflux Questionnaire Revised (I-GERQ-R) score</measure>
    <time_frame>one week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and AUC</measure>
    <time_frame>0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Colic</condition>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepadutant</intervention_name>
    <description>Nepadutant oral solution</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants with a clinical diagnosis of feeding intolerance.&#xD;
&#xD;
          -  Age â‰¤ 6 months at the enrolment.&#xD;
&#xD;
          -  Normal growth.&#xD;
&#xD;
          -  Infants who can refrain from use of erythromycin, metoclopramide, antihistaminic drug,&#xD;
             proton pump inhibitors (PPIs), antacids, antimuscarinic drugs, simethicone and&#xD;
             dimethicone from 1 week prior randomization until end of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant event (excluding those relevant to the condition under study)&#xD;
             which has occurred within one week prior to randomization.&#xD;
&#xD;
          -  Any pharmacological treatment starting within one week prior to randomization.&#xD;
&#xD;
          -  Infants for whom a change in the diet (i.e. weaning) has been performed within one&#xD;
             week prior to randomization or is planned during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Blumer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Toledo Medical Center 3000 Arlington Avenue, Toledo OH 43614 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Center for Digestive Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit / University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Toledo College of Medicine\The Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2012</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Feeding intolerance</keyword>
  <keyword>Infant</keyword>
  <keyword>tachykinin antagonist</keyword>
  <keyword>Infant colic</keyword>
  <keyword>Nepadutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MEN 11420</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 3, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>September 22, 2015</submitted>
    <returned>October 20, 2015</returned>
    <submitted>May 11, 2021</submitted>
    <returned>June 9, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

